How fast does semaglutide work?

Two timelines run at the same time

Semaglutide affects appetite and body weight through two overlapping but distinct processes, and understanding both helps set realistic expectations. Appetite suppression, the quieting of hunger signals and food cravings, typically begins within the first one to four weeks of treatment, according to Mayo Clinic Diet. Measurable weight loss on the scale follows more slowly, governed almost entirely by how quickly the dose escalates toward its maintenance level. Most people experience minimal scale change in the first four weeks, not because the drug is failing, but because the starting dose is intentionally set below therapeutic levels.

Thinking of these two timelines separately prevents the most common source of early discouragement. Reduced appetite is a sign the drug is beginning to work. The scale catches up once the dose climbs. Together, these two processes operate across months, not days, and both peak after the full maintenance dose is established. In the STEP 1 clinical trial of Wegovy (semaglutide 2.4 mg), participants lost nearly 15 percent of their starting body weight by week 68 of treatment, with the sharpest phase of weight loss occurring in months four through fourteen, not month one. These figures are for FDA-approved Wegovy; compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials.

What happens in the first few days

Semaglutide reaches peak blood concentration within one to three days of a subcutaneous injection, according to pharmacokinetic data in the Wegovy prescribing information. At that point it is already binding to GLP-1 receptors in the hypothalamus, the gut, and the pancreas. These receptors regulate hunger signals, stomach-emptying speed, and insulin release. Even at the lowest starting dose of 0.25 mg, some people notice a slight reduction in hunger or earlier fullness at meals within the first three to seven days, though the effect at this dose is subtle.

What most people do not feel in the first week is meaningful weight loss. The 0.25 mg dose is explicitly described in the Wegovy prescribing information as a starting dose for tolerability, not a treatment dose. Its purpose is to allow the gastrointestinal system to adapt before doses climb toward therapeutic levels. Some nausea, mild bloating, or a reduced desire to eat large meals may appear, and that is an early signal the drug is biologically active. A lack of dramatic hunger changes in week one is normal and not a reason for concern.

Weeks 1 through 16: why dose titration deliberately slows early progress

The most important factor controlling how fast semaglutide works for weight loss is the legally required dose escalation schedule. The Wegovy prescribing information specifies that doses increase every four weeks across five steps before the full 2.4 mg maintenance level is reached. At that schedule, a person beginning treatment does not reach the maintenance dose until week 17. Most of the measurable weight loss in clinical trials came after this point, once the dose stabilized at the level studied in the STEP trials.

If gastrointestinal side effects become difficult to manage at any step, the prescribing information allows for a four-week delay before the next dose increase. Tolerability and weight loss work somewhat at cross-purposes in the short run: the slower the escalation, the milder the side effects, but also the longer before the maintenance dose is reached. This is a conversation to have with a prescribing clinician, not a reason to push the schedule faster on one's own.

Months four through seventeen: when most weight loss occurs

Once the 2.4 mg maintenance dose is established, weight loss accelerates substantially. In the STEP 4 trial published in JAMA, participants who completed a 20-week run-in period on semaglutide 2.4 mg (Wegovy) had lost a mean of 10.6 percent of their starting body weight by that point. Those who continued full-dose semaglutide through the 68-week mark ultimately lost an average of approximately 17.4 percent from their original baseline, with the additional loss accumulating steadily during months five through seventeen. Because STEP 4 enrolled only participants who had already completed a 20-week run-in on semaglutide without discontinuing, this figure reflects a tolerant, adherent completer population and is not directly comparable to the 14.9 percent mean in STEP 1, which was measured on an intention-to-treat basis. These figures apply to FDA-approved Wegovy; compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials.

In the STEP 1 trial, the final 68-week result for Wegovy 2.4 mg was a mean weight loss of 14.9 percent compared to 2.4 percent with placebo, as reported in the New England Journal of Medicine. The weight loss curve in that trial continued declining until approximately week 60 before leveling off. This means that someone measuring their results at week 16 or even week 24 is looking at an incomplete picture. The drug's weight-loss effects are not front-loaded. Patience through the titration phase pays off over months five through fourteen, not in the opening weeks.

Why trial averages can mislead individual patients

The 14.9 percent average weight loss figure from STEP 1 is widely cited, but it describes a distribution, not a ceiling or a floor. In that trial, the standard deviation around that average was 9.3 percentage points, meaning a substantial portion of participants lost far less and another group lost considerably more. About 50.5 percent of semaglutide participants reached 15 percent or greater weight loss by week 68, while 7.6 percent lost less than 5 percent of their starting weight across the full trial.

The relationship between early and late response is also more forgiving than many people expect. An analysis of STEP 4 data published in PMC found that among participants who had not reached 5 percent weight loss at week 20, approximately 43 percent still achieved that threshold or higher by week 68 with continued treatment. A slow start does not predict a poor outcome. The prescription not to draw conclusions too early applies most urgently in the first five months, which is entirely within the titration and early maintenance window.

Six factors that shape how quickly someone responds

Several patient characteristics are associated with faster or slower weight loss on semaglutide in clinical trial data. Understanding them helps interpret a personal trajectory without over-reading short-term fluctuations.

• Type 2 diabetes status. In the STEP 2 trial of Wegovy 2.4 mg in adults with type 2 diabetes, mean weight loss was approximately 9.6 percent at week 68, compared with 14.9 percent in the non-diabetic STEP 1 population, as noted in a STEP trials comparison published in Nutrients. The difference is consistent across anti-obesity medications and may involve altered energy expenditure and glycosuria.
• Sex. A sub-analysis of the STEP-HFpEF trial reported by the American College of Cardiology found that women experienced a mean weight reduction of 9.6 percent compared with 7.2 percent in men when using semaglutide 2.4 mg. This was a heart failure population, and patterns may differ in individuals without heart failure.
• Dose adherence. Skipping injections or reducing the dose without clinical guidance limits the drug's continuous action on GLP-1 receptors and interrupts the steady state that maximizes appetite suppression.
• Dietary quality. Semaglutide is prescribed as an adjunct to a reduced-calorie diet and increased physical activity. A person eating significantly more calories than their body burns can partially offset the appetite-driven calorie reduction the drug creates.
• Exercise. Resistance training in particular helps protect lean muscle mass during weight loss, which preserves resting metabolic rate and makes the drug's calorie deficit more effective over time.
• Sleep and stress. Poor sleep and chronic stress both elevate cortisol and can blunt weight loss, independent of the drug's mechanism. Managing these factors supports the overall response.

What clinical trial data covers - and what it does not

Every timeline and percentage discussed in this article comes from clinical trials of Wegovy, an FDA-approved semaglutide product at 2.4 mg produced by Novo Nordisk. These trials, including STEP 1, STEP 2, STEP 4, and the STEP 1 extension, were conducted under controlled conditions with a specific formulation, dose, and administration schedule that was evaluated by the FDA for safety and efficacy prior to approval.

Compounded semaglutide, which is prepared by licensed compounding pharmacies and available through telehealth prescribers, is not FDA-approved and has not been evaluated in equivalent clinical trials. Per FDA guidance, compounded medications are not reviewed by the FDA for safety, efficacy, or quality before dispensing. The timelines, average weight loss figures, and response rates described throughout this article cannot be directly applied to compounded formulations. A licensed clinician can help weigh options based on individual health circumstances and the current regulatory environment for compounding.

The 12-week full-dose checkpoint

Clinicians use a specific benchmark to evaluate whether a patient's response to semaglutide is adequate: less than 5 percent weight loss after 12 weeks of treatment at the full maintenance dose is considered a non-response threshold, according to a clinical guidance review in Advances in Therapy. Because the full 2.4 mg maintenance dose is not reached until week 17, this checkpoint falls around week 29 of a standard titration schedule. Evaluating response before that point, during dose escalation, gives an incomplete picture.

It is also worth noting that in STEP 1, roughly 7.6 percent of trial participants receiving Wegovy still lost less than 5 percent of their starting body weight across the full 68 weeks. Non-response to semaglutide does occur, even at the therapeutic dose. When that happens, a prescribing clinician can consider adjusting the dose, reviewing lifestyle factors, checking for medications or health conditions that could be attenuating the response, or discussing alternative treatments. These are clinical decisions that require a provider conversation, not self-directed dose changes.

When to bring a concern to your provider

Several situations warrant a conversation with a prescribing clinician rather than waiting through the standard timeline.

• No appetite change by week four to six, even at the 0.5 mg dose. Some reduction in hunger is expected by this point, even if subtle. A total absence of any effect is worth mentioning.
• Side effects preventing dose escalation. If nausea, vomiting, or diarrhea are severe enough that the scheduled dose increase cannot happen, a clinician can authorize a four-week delay at the current level, which is within the standard prescribing guidance rather than a deviation from it.
• Less than 5 percent weight change at week 29 or after 12 weeks at the full 2.4 mg dose. This is the recognized clinical threshold for reassessment. A provider may review whether the diagnosis, the dose, or an interfering factor needs to be addressed.
• New medications or health changes. Conditions such as hypothyroidism, steroid use, or new psychiatric medications can affect weight independently of semaglutide and should be communicated to the care team.
• Any symptom causing concern, including persistent abdominal pain, vision changes, or rapid heart rate. These warrant prompt clinical evaluation regardless of the weight loss timeline.

The decision to start, stop, or change any medication, including semaglutide, should be made in partnership with a licensed clinician who has reviewed a patient's full medical history.

What a realistic semaglutide timeline looks like

Pulling together the verified clinical trial data provides a reasonable benchmark for anyone starting or evaluating treatment. These figures apply to Wegovy (semaglutide 2.4 mg) in the STEP trial populations, not to compounded semaglutide formulations, which have not been evaluated in equivalent trials.

Individual results vary considerably, as reflected by the standard deviation of 9.3 percentage points around the STEP 1 mean. Comparing a personal result at week eight to a headline 68-week average is not a valid measure of whether the treatment is working. The clinical benchmark to track is 5 percent or more weight loss at week 29, after 12 weeks at the full maintenance dose. Everything before that point is still the setup phase.